Background. Acute gastroenteritis (AGE) is a leading infectious cause of morbidity worldwide, particularly among children in developing countries. With the decline of rotavirus disease rates following introduction of rotavirus vaccines, the relative importance of norovirus will likely increase. Our objectives in this study were to determine the incidence and clinical profile of norovirus disease in Guatemala.
Acute gastroenteritis (AGE) is a major infectious cause of death globally, particularly in developing countries such as Guatemala [1] . Young children are especially at risk of severe AGE, potentially leading to dehydration, hospitalization, and death [2, 3] . After respiratory illnesses, AGE is 1 of the top 2 reasons for seeking care at a government health facility in Guatemala and was responsible for 1293 deaths in 2016 [4, 5] . Noroviruses have been identified as a leading cause of AGE outbreaks and sporadic disease worldwide [6, 7] . Incidence estimates of total norovirus disease in the community are primarily restricted to developed countries and range from 3800 per 100 000 person-years (py) in the Netherlands to 10 400 per 100 000 py in Canada [7] [8] [9] . Based on recent estimates from the World Health Organization (WHO), there are approximately 200 000 norovirus-associated deaths annually worldwide, of which 99% occur in developing countries [10] . As the disease rates for rotavirus decline following introduction of rotavirus vaccination into national immunization programs, the relative importance of norovirus will likely increase [11, 12] .
Despite the apparent high burden of illness due to AGE, data on disease incidence from specific AGE agents such as norovirus are relatively sparse, particularly in developing countries [13, 14] . In Guatemala, as in most developing countries, epidemiological knowledge of norovirus incidence is lacking, primarily because laboratory diagnosis is not widely available. Molecular techniques, such as real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR), are the preferred methods for definitive diagnosis of norovirus, but these methods are not widely available in clinical practice. Evaluation of norovirus AGE incidence is further limited by the fact that most patients who suffer from AGE do not seek medical care, and when patients do present for care, fecal specimens are rarely collected for diagnostics [15] . Better understanding of the relative role of norovirus among persons who seek medical care is needed in order to prioritize limited public health resources and effectively target prevention strategies, including candidate norovirus vaccines [16] . Moreover, understanding the clinical profile and common patient characteristics in cases of norovirus disease can help in guiding appropriate patient management.
The Centers for Disease Control and Prevention (CDC), in collaboration with the Guatemalan Ministry of Public Health and Welfare and the Center for Health Studies, Universidad del Valle de Guatemala (UVG), started conducting active facility-based surveillance for diarrheal diseases in Guatemala in 2007 [17] . This surveillance platform has been used previously to describe the prevalence and genetic diversity of noroviruses among patients with AGE in Guatemala [18] . Building on these previous efforts, our aim in this study was to determine the incidence and clinical profile of norovirus disease in Guatemala, including estimated rates of community, outpatient, and hospitalized AGE due to norovirus.
METHODS

Study Population
This study, which has been approved by the Human Subject Research Office at CDC (protocol 5150) and the Universidad del Valle de Guatemala, was conducted in government hospitals and outpatient clinics in Santa Rosa and Quetzaltenango. These sites provide a diversity of socioeconomic status and ethnicities that are generally representative of populations in Guatemala. Additional details about the study population and surveillance facilities are reported elsewhere [17] . Surveillance data from complete years of 2008-2013 in Santa Rosa and 2010-2013 in Quetzaltenango were used for this analysis.
Recruitment and Enrollment
Hospitalized patients were enrolled from the inpatient departments of the participating hospitals. Surveillance nurses identified potential cases in the emergency department and by reviewing the inpatient registers on each service using a list of suspect diagnoses and symptoms. All patients who presented at one of the surveillance sites with AGE, defined as ≥3 liquid stools in a 24-hour period that initiated within 7 days before presentation, were enrolled in the study if they gave informed consent. Patients who had another episode of diarrhea in the 7 days before the start of the current episode were excluded to avoid double counting of what was likely a continuation of that same episode. Patients who presented to outpatient clinics were enrolled in a similar manner.
Demographic and Clinical Characteristics
Demographic and clinical data were collected using information from the patient's chart and from the surveillance questionnaire. We defined the clinical characteristics and severity of AGE at the time of enrollment by adapting a modified Vesikari scoring system [19, 20] . This scheme contains the following features: duration of diarrhea in days, maximum number of stools in a 24-hour period, duration of vomiting in days, maximum number of vomits in a 24-hour period, maximum temperature, level of dehydration, and treatment necessity. These features were all scored independently and then summed, with a maximum score of 20 and a score of >11 defined as severe disease [19, 21] . For assessment of severity scores, patients were grouped into the following categories: norovirus only, rotavirus only, nonviral (negative for both norovirus and rotavirus), mixed (positive for 2 or more of norovirus, rotavirus, or nonviral etiology), and unknown (negative for all pathogens).
Sample Collection and Laboratory Testing
A whole stool sample of ≥5 g was requested from all enrolled patients with AGE. Samples from outpatient clinics were stored in an insulated cooler at 4°C until transported to participating hospitals within 24 hours of collection. At the hospital, stool samples were aliquoted into appropriate media or kept fresh and maintained at 4°C with refrigeration until weekly transport to the laboratories at UVG.
Stool samples were tested for parasites by direct smear examination of fresh stool, for bacteria (eg, Salmonella, Shigella, Campylobacter) by direct culture, for Escherichia coli with conventional PCR, and for rotavirus by using a commercial qualitative enzyme immunoassay (IDEIA Rotavirus test kit, Oxoid Ltd., Ely, United Kingdom) [17] . Testing for norovirus (genogroups I and II) was performed using RT-qPCR [22] , and quality control assessments were performed at the UVG laboratories [18] .
Household Surveys
Household surveys were conducted in Santa Rosa and Quetzaltenango to obtain information on healthcare-seeking behaviors for AGE and to develop adjustment factors for incidence rate calculations. Details on these surveys are described elsewhere [17] and in the Supplementary Materials. Briefly, the surveys included questions about episodes of AGE in all members of the household, healthcare-seeking practices and treatments during AGE episodes, and demographic characteristics of household members. From these data, we estimated the proportion of AGE cases in the community that were consistent with norovirus disease (ie, nonbloody diarrhea lasting ≤3 days duration) who sought health care and, of those, the proportion who sought care at a study facility, stratified by age group (<5 years and ≥5 years).
Incidence Rate Calculations
We generated estimates of hospital, outpatient, and total community incidence based on the observed incidence in surveillance facilities and age group-specific adjustment factors from the household surveys. Estimates of hospitalized and outpatient norovirus incidence were calculated based on the number of eligible cases who presented to surveillance clinics, the proportion of those patients tested for norovirus who were positive, the annual population estimates for the catchment area, and the proportion of medically attended AGE cases for which healthcare was sought at study facilities using the following equation: To estimate community incidence, we modified the above equation by replacing the proportion of medically attended cases who sought care at study facilities with the proportion of total community AGE cases who sought care at study facilities. This term accounts for both care seeking in general and specifically seeking care at study facilities. Thus, the equation for community incidence was as follows: Age-stratified (ie, <5 vs ≥5 years) norovirus prevalence and healthcare use rates were weighted based on the number of eligible AGE patients in each age strata to generate overall incidence rates. Age-stratified census data for the specific catchment jurisdictions were available for 2002, but only total population estimates were available for subsequent years [23] .
Thus, we assumed that the age distribution was proportionally unchanged and applied the percentage in each age group from 2002 to the total population estimates in subsequent years to generate age group-specific estimates for those years. All analyses were performed using SPSS Statistic 22 (IBM, Armonk, New York) or in SAS, version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
Of 7135 eligible patients who presented with AGE in Santa Rosa during 2008-2013 and in Quetzaltenango during 2010-2013, 6502 (91%) were enrolled in the surveillance study. Of those 6502 patients, 4188 (64%) provided a whole stool sample of adequate volume and were tested for norovirus, including 999 hospitalizations and 3189 outpatient clinic visits. Norovirus was detected in 164 (16%) AGE hospitalizations and 370 (12%) AGE outpatients. Despite testing for viruses, bacteria, and parasites, an infectious etiology was not identified in 2478 (59%) patients.
Demographic Characteristics
Most patients included in the study were aged <5 years (2605 patients, 62%), with elevated norovirus prevalence rates in both hospital (19%) and outpatient (15%) settings (Table 1) . Norovirus prevalence was greatest among hospitalized and outpatient infants aged <1 year (22% and 19%, respectively) and generally decreased with increasing age. Male patients comprised 57% of hospitalized patients but only 44% of outpatients; across both settings, male patients had higher rates of norovirus detection. Most (70%, n = 2933) patients lived in a household with a monthly family income of less than $130.00, although norovirus prevalence was similar across income groups and ethnicities.
Clinical Profile
The median severity score among the 406 patients with a norovirus monoinfection was 7, and the median severity score among rotavirus patients was 9 due primarily to more severe dehydration and more frequent hospitalization among rotavirus patients (Table 2) . Additionally, most (56%) norovirus patients did not have a fever. Vomiting was more prevalent among norovirus and rotavirus patients (73% and 77%, respectively) than among patients with nonviral etiologies (55%), although vomiting typically lasted only 1 day. Clinically apparent dehydration was more prevalent among norovirus patients (15%) and particularly rotavirus patients (36%) compared with patients with a nonviral etiology (5%). Similarly, 32% of norovirus patients and 52% of rotavirus patients were hospitalized, while only 12% of nonviral patients were hospitalized. Overall, Positive for rotavirus and negative for norovirus, bacteria, and protozoa. c Positive for bacteria (Campylobacter, Salmonella, Shigella) or protozoa (Giardia, Cryptosporidium) but not norovirus or rotavirus. 16% of norovirus patients had severe AGE (modified Vesikari score ≥11) compared with 32% of rotavirus patients and 5% of nonviral patients.
Incidence Rate Estimates
Across both surveillance sites, children aged <5 years had higher incidence rates of norovirus than older children and adults (Table 3 ). In Santa Rosa, incidence of norovirus-associated hospitalization was 105 per 100 000 py among children aged <5 years but only 1.6 per 100 000 py among people aged ≥5 years. Similarly, norovirus-associated outpatient incidence was 2207 per 100 000 py in children aged <5 years and 80 per 100 000 py in those aged ≥5 years. Adjusting for healthcare use rates ascertained through household surveys, total community incidence rates of norovirus in Santa Rosa were 4954 per 100 000 py in children aged <5 years and 414 per 100 000 py in persons aged ≥5 years. Overall, for each norovirus-associated hospitalization in Santa Rosa, there were approximately 22 norovirus-associated outpatient clinic visits and 98 total community cases of norovirus disease.
Norovirus incidence rates in Quetzaltenango were generally lower than those in Santa Rosa. Incidence of norovirus-associated hospitalization in Quetzaltenango was 51 per 100 000 in children aged <5 years; norovirus was not detected among any hospitalized AGE patients aged ≥5 years in Quetzaltenango. Incidence of norovirus-associated outpatient visits in Quetzaltenango was 632 per 100 000 py in children aged <5 years and 49 per 100 000 py in persons aged ≥5 years. Similar to the pattern observed in Santa Rosa, total community incidence of norovirus in Quetzaltenango was 10 times greater in children aged <5 years (2068 per 100 000 py) than in those aged ≥5 years (206 per 100 000 py). The overall ratio of hospitalized to outpatient to total community cases of norovirus disease in Quetzaltenango (1:20:100) was similar to that in Santa Rosa.
DISCUSSION
Across the 2 study sites in Guatemala, we estimated total community incidence of norovirus to be 609-1635 per 100 000 py, with approximately 1% of those cases requiring hospitalization. Proportion of AGE patients enrolled at surveillance facilities and tested for norovirus who yielded positive results, age weighted based on number of eligible AGE patients. c Census-based estimates of the catchment populations in the respective jurisdictions for the years of observation [17, 23] . Estimated proportion of AGE cases in each setting and site who sought care at surveillance facilities, age weighted based on the number of eligible AGE patients.
Norovirus community incidence in children aged <5 years was about 10 times greater than that in people aged ≥5 years. This difference in age-specific incidence was even more pronounced among medically attended norovirus cases. Across the various outcomes and age groups, norovirus incidence rates in Santa Rosa were 2-4 times greater than those in Quetzaltenango due, at least in part, to differences in healthcare use between the 2 study sites. The clinical severity of norovirus disease among medically attended AGE patients was similar to that caused by other pathogens, with the exception of rotavirus, which tended to be more severe.
Comparisons with estimates of norovirus incidence from other studies are complicated by different methodological approaches and data sources. For example, a study in southwest Guatemala used 2 surveillance methods to estimate norovirus incidence, which yielded estimates that differed by 2 orders of magnitude (1.4-154 per 100 py) [24] . Nonetheless, our estimates of medically attended norovirus incidence in Guatemala are consistent with those reported for developed countries. Across our study sites, we estimated 6-17 norovirus-associated hospitalizations per 100 000 py and 124-364 norovirus-associated outpatient visits per 100 000 py. For comparison, norovirus hospitalization rates reported in developed countries range from 12-24 per 100 000 and norovirus outpatient visit rates range from 92-640 per 100 000 [7, 8, 25] . Our estimates of norovirus community incidence are likewise broadly similar to, albeit somewhat lower than, those reported in developed countries, which range from 3800 per 100 000 in the Netherlands to 10 400 per 100 000 in Canada [8, 9, 26] . As estimates of community incidence generally rely on extrapolation from medically attended incidence, they can vary substantially depending on the healthcare use rates used as multipliers. Differences in healthcare systems between countries thus make it difficult to directly compare country-specific estimates.
The highest rates of both medically attended and total community norovirus disease were observed in children aged <5 years. Based on these incidence estimates, by the age of 5 years, as many as 1 in 9 Guatemalan children will have a medically attended bout of norovirus disease. These findings are consistent with those from previous studies that indicate that norovirus is an important cause of sporadic acute gastroenteritis in children [10, 12] . In the European Union, the total number of hospitalizations due to norovirus was estimated to be 14 per 10 000 in children aged <5 years of age, leading to 37 000 norovirus-attributable hospitalizations in these children every year [27] . These elevated rates of disease and hospitalization in children suggest increased frequency of exposure, perhaps due to inferior hygiene habits, and greater susceptibility to infection and more severe outcomes. These rates also reflect higher rates of healthcare seeking among children.
Consistent with previous studies in developed countries, norovirus was associated with a lower severity of AGE compared with diarrhea caused by rotavirus in Guatemala [21] . Nonetheless, vulnerable populations, such as the elderly and young children, have longer recovery times and are more at risk for associated hospitalization and mortality. Fatalities have also been reported in association with outbreaks among the elderly in nursing home facilities [28] . Based on recent estimates from the WHO, there are 54 214 norovirus-associated deaths among children aged <5 years annually worldwide, of which 98% occur in developing countries [10] . Thus, there is a wide spectrum of disease severity that can result from norovirus infection, despite a tendency toward milder illness compared with some other AGE pathogens.
In this study we used a relatively robust approach to estimate the incidence of norovirus disease. Nonetheless, the study has several limitations that should be taken into account. First, the extrapolation from observed incidence in surveillance facilities using household surveys may not be representative of all cases. Additionally, these surveys were limited by sample size and recall bias. Second, about onethird of the patients identified through facility-based surveillance were not tested for norovirus, which might have led to selection bias. Furthermore, it is possible that cases were discharged before they could be screened by study staff, resulting in potential underestimation of incidence. For the incidence calculations stratified by age group, we used the age-stratified national census data from 2002 and thus could not account for changes in the age distribution in subsequent years. Finally, asymptomatic norovirus infections do occur; however, we did not have a control group with nondiarrheal stool specimens to estimate the attributable fraction of AGE caused by norovirus. However, based on previous characterization of an earlier collection of stool samples from the same sites in Guatemala, approximately 80% of norovirus infections among diarrhea patients occurred without detection of any other known pathogens [18] . A recent study of AGE among children in southwest Guatemala found that 20% of samples were positive for norovirus compared with 11% of samples from children without AGE [29] . These findings are consistent with a recent global review and metaanalysis of norovirus prevalence studies, which found norovirus was detected more frequently among cases of AGE (20%) than among healthy controls (7%) [30] . In the absence of control data in the current study, we assume that norovirus contributed to disease whenever detected among medically attended AGE patients, which is consistent with previous norovirus incidence rate estimates from similar surveillance systems [14] .
Overall, our results highlight the importance of norovirus as a causative agent for AGE in Guatemala, especially among younger children. The disease burden of norovirus in this setting indicates the need for further prevention strategies. The findings from our study can help inform cost-effectiveness and modeling studies to further define a public health strategy for controlling norovirus disease, including the potential use of vaccines. Furthermore, these incidence estimates provide a baseline to which the impact of such interventions can be subsequently measured.
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